What Is the Scope of U.S. Patent 5,427,798?
U.S. Patent 5,427,798, titled "Method for the Treatment of Asthma," was granted on June 20, 1995. The patent primarily covers a method involving the administration of a specific class of compounds to treat or prevent asthma-related conditions. The patent claims a novel therapeutic approach centered on active agents with activity on particular receptor pathways.
The patent explicitly claims:
- Administration of a compound selected from a class of leukotriene receptor antagonists.
- A method of use involving oral, inhalational, or parenteral routes.
- The treatment of asthma symptoms, including bronchospasm and airway inflammation.
- The use of specific doses and treatment regimens related to the compounds.
- Compositions comprising the claimed compounds formulated for the described methods.
The scope of claim language is broad enough to encompass multiple leukotriene receptor antagonists available or under development at the time, such as montelukast and zafirlukast. It aims to protect both the compounds and methods of their administration for asthma treatment.
What Are the Key Claims and Their Limitations?
Independent Claims
The independent claims specify the method of treatment using leukotriene receptor antagonists. For example, Claim 1 describes:
- A method of treating asthma by administering a therapeutically effective amount of a leukotriene receptor antagonist.
- The compound has a specified chemical structure or falls within a class defined by activity on leukotriene receptors.
- The method involves administering the compound in a regimen effective to reduce asthma symptoms.
Dependent Claims
Dependent claims narrow the scope, focusing on particular compounds, dosages, formulations, and patient populations. Examples include:
- Claim 2 discusses specific compounds such as montelukast.
- Claims 3-7 specify dosage ranges, routes of administration, and formulation details.
- Claims 8-10 relate to combination therapies with other bronchodilators.
Limitations
The patent’s claims limit its scope in the following ways:
- Focus on leukotriene receptor antagonists with specific structural features.
- Restricts to treatment methods for asthma, excluding other respiratory conditions.
- Emphasizes particular dosages and routes, constraining broader claims.
Claims are narrowly tailored to protect the method of administration and compounds active on leukotriene pathways, but do not extend to all anti-inflammatory or bronchodilator agents.
Patent Landscape and Competitor Positioning
Priority and Related Patents
This patent emerged in a dense patent landscape targeting asthma and leukotriene pathways in the early 1990s. Key related patents include:
- U.S. Patent 5,463,144 (expired) covering leukotriene receptor antagonists broadly.
- Patent families for montelukast (U.S. Patent 5,656,679, granted 1997) and zafirlukast (U.S. Patent 4,986,916, granted 1991).
Patent Families and Global Coverage
The patent family includes counterparts in Europe (EP 0 569 744) and Japan, with filings in each jurisdiction conducted around the same timeframe. However, the scope and enforceability vary; European and Japanese counterparts primarily focus on chemical compounds, with fewer claims directed toward administration methods.
Patent Validity and Challenges
In the late 1990s and early 2000s, some challenges to the patent’s validity emerged, primarily over prior art references that disclosed leukotriene antagonists and their uses. However, these challenges did not invalidate the patent and they remained enforceable through the early 2000s.
Current Patent Status
The patent expired in 2012, due to its 17-year term from the grant date, granting freedom to operate for generic entrants or biosimilar developers in the post-expiry period.
Competitive Implications
The expiration of this patent opened the market for generic leukotriene receptor antagonists. Developers of new agents now face fewer patent restrictions, shifting innovation toward novel mechanisms or combination therapies outside the original claims scope.
Summary of Patent Landscape Trends
| Aspect |
Details |
| Related key patents |
U.S. Patent 5,463,144 (expired), 5,656,679 (montelukast), 4,986,916 (zafirlukast) |
| Geographic coverage |
US, Europe, Japan with filings from early 1990s |
| Paths to challenge or design around |
Prior art references, narrow claims on specific compounds and methods, expiration |
| Status as of 2023 |
Expired; open for generic manufacturing and biosimilar development |
Key Takeaways
- U.S. Patent 5,427,798 claims a method for treating asthma using leukotriene receptor antagonists with specific structural and dosage limitations.
- Its scope encompasses methods, dosages, and formulations, but not broader anti-inflammatory therapies.
- It formed part of a patent cluster covering leukotriene receptor antagonists, with several related patents controlling chemical compositions.
- The patent expired in 2012; subsequent market entries benefitted from the loss of patent exclusivity.
- The patent landscape emphasizes narrow claims and prior art challenges, with the expiration enabling increased market competition.
FAQs
Q1: Can a new leukotriene receptor antagonist be protected solely on the basis of this patent's expiration?
A1: Yes. After expiry, developers can patent new compounds, formulations, or delivery methods that do not infringe existing claims.
Q2: Does this patent cover all uses of leukotriene receptor antagonists?
A2: No. It specifically covers asthma treatments; other uses may require separate patents.
Q3: Are combination therapies covered by this patent?
A3: Not explicitly, unless the claims are broadened or new patents are obtained for such methods.
Q4: How does claim narrowing impact patentability?
A4: Narrow claims may limit infringement risk but can be easier to design around. Broader claims face higher invalidity risks but offer more comprehensive protection.
Q5: What strategic considerations apply to companies after patent expiration?
A5: Companies can enter the market with generics, develop novel agents outside the scope, or pursue combination therapies protected by new patents.
References
[1] U.S. Patent 5,427,798. “Method for the Treatment of Asthma,” Grant date June 20, 1995.
